Dicyclomine — Membership Pricing
Dicyclomine is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Dicyclomine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $89.99 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Dicyclomine
Dicyclomine is a prescription medication. Ask your doctor if Dicyclomine is right for you.
Other strengths and forms of Dicyclomine
Conditions Treated with Dicyclomine
- Biliary Colic
- Biliary colic (adjunct)
- Diarrhea‑predominant IBS
- Functional abdominal pain
- Intestinal spasm
- Irritable Bowel Syndrome
- Irritable bowel syndrome (cramping)
- Irritable Bowel Syndrome (Diarrhea-Predominant/Cramping)
How to Check Dicyclomine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Dicyclomine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Irritable Bowel Syndrome
Other medications in Gastrointestinal
What Dicyclomine is approved for (FDA label)
Dicyclomine hydrochloride tablets are indicated for the treatment of patients with functional bowel/irritable bowel syndrome. Dicyclomine hydrochloride tablets are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: September 10, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Dicyclomine (FDA label)
Dicyclomine hydrochloride, USP 20 mg tablets: Blue, Round, Unscored Tablet; Debossed “WW 27” Dicyclomine hydrochloride tablets, USP 20 mg ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 6d7e73b0-3f7e-462f-92eb-cc82919c8095. SPL document ID: 14fe8389-11d7-49d9-94af-a6f164a77692. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Dicyclomine (FDA label)
The pattern of adverse effects seen with dicyclomine is mostly related to its pharmacological actions at muscarinic receptors [see Clinical Pharmacology ( 12 )] . They are a consequence of the inhibitory effect on muscarinic receptors within the autonomic nervous system. These effects are dose-related and are usually reversible when treatment is discontinued. The most serious adverse reactions reported with dicyclomine hydrochloride include cardiovascular and central nervous system symptoms [see Warnings and Precautions ( 5.2 , 5.3 )]. The most serious adverse reactions include cardiovascular and central nervous system symptoms. The most common adverse reactions (> 5% of patients) are dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.com 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 6d7e73b0-3f7e-462f-92eb-cc82919c8095. SPL document ID: 14fe8389-11d7-49d9-94af-a6f164a77692. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Dicyclomine (FDA label)
Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age [see Use in Specific P opu l a ti on s ( 8.4 )], nursing mothers [see Use in Specific Populations ( 8.3 )] and in patients with: • unstable cardiovascular status in acute hemorrhage • myasthenia gravis [see Warnings and Precautions ( 5.4 )] • glaucoma [see Adverse Reactions ( 6.3 ) and Drug Interactions ( 7.1 )] • obstructive uropathy [see Warnings and Precautions ( 5.8 )] • obstructive disease of the gastrointestinal tract [see Warnings and Precautions ( 5.5 )] • severe ulcerative colitis [see Warnings and Precautions ( 5.7 )] • reflux esophagitis • Infants less than 6 months of age ( 4 ) • Nursing mothers ( 4 ) • Unstable cardiovascular status in acute hemorrhage ( 4 ) • Myasthenia gravis ( 4 ) • Glaucoma ( 4 ) • Obstructive uropathy ( 4 ) • Obstructive disease of the gastrointestinal tract ( 4 ) • Severe ulcerative colitis ( 4 ) • Reflux esophagitis ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 6d7e73b0-3f7e-462f-92eb-cc82919c8095. SPL document ID: 14fe8389-11d7-49d9-94af-a6f164a77692. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Dicyclomine (FDA label)
Cardiovascular conditions: worsening of conditions ( 5.2 ) Peripheral and central nervous system: heat prostration can occur with drug use (fever and heat stroke due to decreased sweating); drug should be discontinued and supportive measures instituted ( 5.3 ) Psychosis and delirium have been reported in patients sensitive to anticholinergic drugs (such as elderly patients and/or in patients with mental illness): signs and symptoms resolve within 12 to 24 hours after discontinuation of dicyclomine hydrochloride ( 5.3 ) Myasthenia Gravis: overdose may lead to muscular weakness and paralysis. Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase ( 5.4 ) Incomplete intestinal obstruction: diarrhea may be an early symptom especially in patients with ileostomy or colostomy.
Source: FDA prescribing information (DailyMed). Set ID: 6d7e73b0-3f7e-462f-92eb-cc82919c8095. SPL document ID: 14fe8389-11d7-49d9-94af-a6f164a77692. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Dicyclomine (FDA label)
Antiglaucoma agents : anticholinergics antagonize antiglaucoma agents and may increase intraoccular pressure ( 7 ) Anticholinergic agents : may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs ( 7 ) Antacids : interfere with the absorption of anticholinergic agents ( 7 ) 7.1 Antiglaucoma Agents Anticholinergics antagonize the effects of antiglaucoma agents. Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.
Source: FDA prescribing information (DailyMed). Set ID: 6d7e73b0-3f7e-462f-92eb-cc82919c8095. SPL document ID: 14fe8389-11d7-49d9-94af-a6f164a77692. Label effective date: September 10, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.